152 related articles for article (PubMed ID: 11816516)
1. [Estimation of the prevalence of low turn over renal osteodystrophy using biological markers in a peritoneal dialysis population].
Negri AL; Alvarez Quiroga M; Bravo M; Fradinger E; Jacobo de Marino A; Bogado CE; Zanchetta JR
Nefrologia; 2001; 21(4):392-4. PubMed ID: 11816516
[No Abstract] [Full Text] [Related]
2. Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol.
Arora N; Sandroni S; Moles K
Adv Perit Dial; 1992; 8():62-4. PubMed ID: 1361854
[TBL] [Abstract][Full Text] [Related]
3. PTH and bone markers of renal osteodystrophy in predialysis chronic renal failure.
Coen G; Mazzaferro S; Ballanti P; Bonucci E
J Endocrinol Invest; 1992; 15(9 Suppl 6):129-33. PubMed ID: 1300330
[No Abstract] [Full Text] [Related]
4. [How to manage mineral metabolism disorders in renal failure].
Jean G
Presse Med; 2011 Nov; 40(11):1043-52. PubMed ID: 21885239
[TBL] [Abstract][Full Text] [Related]
5. Fluoride and dialysis osteodystrophy: results of a double-blind study.
Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA
Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422
[No Abstract] [Full Text] [Related]
6. [Correlations between osteodensitometry and parameters of uremic osteodystrophy].
Sforzini S; Viganò MR; Beretta P; Rosa M; d'Amico P; Lomuscio G; Paesani R
Minerva Med; 1985 Mar; 76(9-10):445-8. PubMed ID: 3982703
[No Abstract] [Full Text] [Related]
7. [Biochemical and histological spectrum of renal osteodystrophy in Argentina].
Douthat WG; Garay G; de Arteaga J; Fernández Martín JL; Cannata Andía JB; Massari PU
Nefrologia; 2003; 23 Suppl 2():47-51. PubMed ID: 12778854
[TBL] [Abstract][Full Text] [Related]
8. Can bone histomorphometry be predicted by clinical assessment and noninvasive techniques in peritoneal dialysis?
Joffe P; Heaf JG; Jensen C
Miner Electrolyte Metab; 1996; 22(4):224-33. PubMed ID: 8807626
[TBL] [Abstract][Full Text] [Related]
9. Compliance with objectives based on different guidelines (KDIGO/S.E.N.) and analysis of the individual variability of mineral metabolism in haemodialysis patients in the medium term.
del Pozo-Fernández C; López-Menchero-Martínez R; Álvarez-Avellán L; Albero-Molina MD; Sánchez-Rodríguez L
Nefrologia; 2013; 33(5):675-84. PubMed ID: 24089159
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for renal osteodystrophy: a multivariant analysis.
Pei Y; Hercz G; Greenwood C; Segre G; Manuel A; Saiphoo C; Fenton S; Sherrard D
J Bone Miner Res; 1995 Jan; 10(1):149-56. PubMed ID: 7747622
[TBL] [Abstract][Full Text] [Related]
11. Managing bone mineral disorders in CKD: an overview of current therapies.
Delaney M
J Ren Care; 2009 Mar; 35 Suppl 1():107-10. PubMed ID: 19222741
[No Abstract] [Full Text] [Related]
12. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
[TBL] [Abstract][Full Text] [Related]
13. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
Bucciante G; Bernardi A; Biasia F; Milan G; Donato D
Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698
[No Abstract] [Full Text] [Related]
14. [Subtotal parathyroidectomy in the treatment of renal osteodystrophy in 8 patients under chronic hemodialysis].
Lillo M
Rev Med Chil; 1984 Jun; 112(6):564-9. PubMed ID: 6515169
[No Abstract] [Full Text] [Related]
15. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
[No Abstract] [Full Text] [Related]
16. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
[TBL] [Abstract][Full Text] [Related]
17. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
[No Abstract] [Full Text] [Related]
18. Renal osteodystrophy in children undergoing continuous ambulatory peritoneal dialysis.
Hewitt IK; Stefanidis C; Reilly BJ; Kooh SW; Balfe JW
J Pediatr; 1983 Nov; 103(5):729-34. PubMed ID: 6631599
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of PTH total kit for estimation of bone turnover in children with chronic renal failure].
Ziółkowska H; Roszkowska-Blaim M
Przegl Lek; 2006; 63 Suppl 3():149-52. PubMed ID: 16898516
[TBL] [Abstract][Full Text] [Related]
20. The evolution of renal osteodystrophy in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Calderaro V; Oreopoulos DG; Meema HE; Ogilvie R; Husdan H; Khanna R; Quinton C; Murray T; Carmichael D
Proc Eur Dial Transplant Assoc; 1980; 17():533-42. PubMed ID: 6787584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
